Skip to content
DraconiticResearch
Search Sources API
190,860 studies31 sourcesUpdated 22 min ago
Peer-reviewedCC BYScientific Reports

Disulfidptosis-related genes stratify molecular subtypes and highlight MYH9 as a prognostic biomarker and candidate therapeutic target in pancreatic ductal adenocarcinoma

  • Xiaoyan Fan1
  • Ming Zhang2
  • Dong Xu3
  • Rujie Chen4
  • Lei Qian1
  • Jun Zhu5
  • Jipeng Li1
5 affiliations
  1. 1Department of Experimental Surgery, The First Affiliated Hospital of Air Force Medical University
  2. 2Xi’an TCM Hospital of Encephalopathy
  3. 3Division of Digestive Surgery, Xi’an International Medical Center Hospital of Digestive Diseases
  4. 4Xizang Military Region General Hospital General Surgery Department
  5. 5Department of Digestive Surgery, The First Affiliated Hospital of Digestive Diseases, Air Force Medical University
Read full textDOICite

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy with limited therapeutic options. This study aimed to explore the role of disulfidptosis‑related genes (DRGs) in shaping the tumor immune microenvironment of PDAC, and to identify candidate prognostic biomarkers with potential therapeutic implications. DRG expression was profiled using transcriptomic data from The Cancer Genome Atlas (TCGA), and consensus clustering identified two molecular subtypes—C1 and C2—with C2 exhibiting a higher disulfidptosis activity score and distinct immune‑related features. Univariate and multivariate Cox regression analyses identified MYH9 as an independent prognostic factor. A nomogram incorporating MYH9 expression, age, gender, AJCC pathological stage, and histological grade predicted 1‑, 2‑, and 3‑year overall survival with areas under the curve (AUC) values of 0.66, 0.80, and 0.64, respectively. Further immune and drug‑sensitivity analyses revealed that MYH9 expression correlated significantly with immune cell infiltration and response to agents such as staurosporine, dasatinib, and oxaliplatin. Experimental validation showed that MYH9 overexpression significantly promoted the proliferation of PDAC cells, whereas MYH9 knockdown markedly suppressed it, and rescue experiments with the MYH9 inhibitor blebbistatin further confirmed its regulatory role in PDAC cell growth. Moreover, clinical specimen validation confirmed that elevated MYH9 expression correlated with reduced CD8+ T cell infiltration and poorer overall survival in PDAC patients. Collectively, these findings indicate that DRG expression profiles are closely associated with the PDAC tumor microenvironment. MYH9, identified from the disulfidptosis‑related gene set, serves as a reliable prognostic biomarker and a candidate oncogene in PDAC. Its potential association with disulfidptosis provides a preliminary basis for further mechanistic investigation and the exploration of targeted therapy for PDAC.

Related

  1. Molecular mechanisms by which the intratumoral microbiome drives pancreatic ductal adenocarcinoma progression and therapeutic response
    Zhonghua Qi, Miaolei Wang, Yajing Li +2
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  2. Prognostic and Spatial Organization of Tertiary Lymphoid Structures in Pancreatic Ductal Adenocarcinoma
    Yunqi Jia, Mengzhe Zhang, Haoran Yang +2
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Myeloid-driven immunosuppression as a context-dependent therapeutic bottleneck in pancreatic ductal adenocarcinoma
    Kai Sun, Lei Yang, Jingjing Li +4
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  4. SPP1-associated pathomics features for prognostic modeling in pancreatic ductal adenocarcinoma
    Jinming Zhao, Mingjun Li, Jialiang Xing +2
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefDOAJ
  5. VDAC1 regulates disulfidptosis susceptibility and associates with the immune microenvironment via multi-omics analysis in lung adenocarcinoma
    Chen Chen, Yuanyuan Yang, Wenjing Fu +1
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref

Cite

BibTeXRIS
BibTeX
@article{fan2026disulfidptosisrelated,
  title = {{Disulfidptosis-related genes stratify molecular subtypes and highlight MYH9 as a prognostic biomarker and candidate therapeutic target in pancreatic ductal adenocarcinoma}},
  author = {Xiaoyan Fan and Ming Zhang and Dong Xu and Rujie Chen and Lei Qian and Jun Zhu and Jipeng Li},
  journal = {Scientific Reports},
  year = {2026},
  month = jul,
  doi = {10.1038/s41598-026-63405-2},
  url = {https://doi.org/10.1038/s41598-026-63405-2},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Disulfidptosis-related genes stratify molecular subtypes and highlight MYH9 as a prognostic biomarker and candidate therapeutic target in pancreatic ductal adenocarcinoma
AU  - Xiaoyan Fan
AU  - Ming Zhang
AU  - Dong Xu
AU  - Rujie Chen
AU  - Lei Qian
AU  - Jun Zhu
AU  - Jipeng Li
PY  - 2026
DA  - 2026/07/01
JO  - Scientific Reports
DO  - 10.1038/s41598-026-63405-2
UR  - https://doi.org/10.1038/s41598-026-63405-2
AB  - Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy with limited therapeutic options. This study aimed to explore the role of disulfidptosis‑related genes (DRGs) in shaping the tumor immune microenvironment of PDAC, and to identify candidate prognostic biomarkers with potential therapeutic implications. DRG expression was profiled using transcriptomic data from The Cancer Genome Atlas (TCGA), and consensus clustering identified two molecular subtypes—C1 and C2—with C2 exhibiting a higher disulfidptosis activity score and distinct immune‑related features. Univariate and multivariate Cox regression analyses identified MYH9 as an independent prognostic factor. A nomogram incorporating MYH9 expression, age, gender, AJCC pathological stage, and histological grade predicted 1‑, 2‑, and 3‑year overall survival with areas under the curve (AUC) values of 0.66, 0.80, and 0.64, respectively. Further immune and drug‑sensitivity analyses revealed that MYH9 expression correlated significantly with immune cell infiltration and response to agents such as staurosporine, dasatinib, and oxaliplatin. Experimental validation showed that MYH9 overexpression significantly promoted the proliferation of PDAC cells, whereas MYH9 knockdown markedly suppressed it, and rescue experiments with the MYH9 inhibitor blebbistatin further confirmed its regulatory role in PDAC cell growth. Moreover, clinical specimen validation confirmed that elevated MYH9 expression correlated with reduced CD8+ T cell infiltration and poorer overall survival in PDAC patients. Collectively, these findings indicate that DRG expression profiles are closely associated with the PDAC tumor microenvironment. MYH9, identified from the disulfidptosis‑related gene set, serves as a reliable prognostic biomarker and a candidate oncogene in PDAC. Its potential association with disulfidptosis provides a preliminary basis for further mechanistic investigation and the exploration of targeted therapy for PDAC.
SN  - 2045-2322
ER  -